Physician profile
Zoe Schultz
NPI 1093140659
$6,081.55
in general payments reported to CMS, 2019-2025
51 companies · $579 in 2025
The $579 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,224 · 2022: $1,210 · 2023: $1,521 · 2024: $1,547 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,647.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $878.24 | 2021-2025 | |
| Novo Nordisk INC | $654.48 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $422.92 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $398.78 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $360.00 | 2021-2024 | Rexulti |
| Abbott Laboratories | $342.39 | 2021-2025 | Freestyle Libre 3, Mitraclip |
| Astellas Pharma US INC | $339.63 | 2021-2025 | Veozah, Myrbetriq |
| Supernus Pharmaceuticals, INC. | $207.93 | 2024-2025 | Qelbree |
| Amgen INC. | $197.49 | 2021-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $187.70 | 2021-2024 | |
| Dexcom, INC. | $171.38 | 2021-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $166.64 | 2021-2024 | Farxiga, Airsupra |
| Pfizer INC. | $137.25 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.96 | 2021-2024 | |
| Corium, LLC | $124.65 | 2024-2025 | Azstarys |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoe Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.